Presently, many smokers, both young and old, are choosing e-cigarettes over conventional ones since they are believed to have less effects on one’s health. Scientists believed that the negative effects of smoking were caused by the chemicals present in the smoke emitted from e-cigarettes. However, a new study, which was conducted by the University of Rochester Medical Center, indicates otherwise. The study, which was led by Irfan Rahman, PhD, indicated that e-cigarettes are as harmful as conventional cigarettes. The experiment involved the exposure of a 3D nonsmoker gum tissue to the vapors of e-cigarettes. The results indicated that vapors from a burning e-cigarette trigger the cells to produce inflammatory proteins, thus stressing cells and causing oral damage. Check the journal at SCImago Journal & Country Rank.
Further, the research proved that flavoring chemicals cause oral damage. Professor Rahman, who also conducted a research on the effects of e-cigarettes on lung cells, said that various flavoring chemicals affect gum cells differently. He added that the extent of damage caused by e-cigarettes depends on the frequency of smoking. Rahman expressed the need for more research on the same study. He suggested that manufacturers should indicate all the ingredients used to develop their products and inform smokers on the possible effects of the same. The study, which was funded by the National Institutes of Health, included contributors like Fawad Javed of the Eastman Institute for Oral Health, Isaac K. Sundar of UR department of environmental medicine, and Georgios E. Romanos of Stony Brook University’s School of Dental Medicine in the department of periodontology.
Oncotarget is an online peer-reviewed journal that publishes research studies on oncology and beyond. The free-access monthly journal accepts papers on cardiology, metabolism, neuroscience, endocrinology, cell biology and pharmacology. Scientists are able to maximize the impact of their research through timely and constructive peer-reviews. By publishing their research papers on Oncotarget, authors benefit from the recommendations made by the company’s editors. Mikhail Blagosklonny is one of the editors-in-chief of the journal. He has vast experience in matters oncology. The journal encourages the application of basic and clinical science in the treatment and prevention of illnesses. Notably, Oncotarget focuses on determining the use of targeted cancer therapies. The articles posted on the journal have been beneficial to other researchers, and the general public. Visit Oncotarget’s profile page at facebook.com